SLC7A11 and neoplasm: IFN-γ down-modulates the expression of SLC3A2 and SLC7A11 and inactivates cystine uptake, in turn promoting lipid peroxidation and ferroptosis in tumor cells and increasing the clinical benefit of cancer immunotherapy [178].